Ryan J. Watts Sells 18,333 Shares of Denali Therapeutics Inc (NASDAQ:DNLI) Stock

Denali Therapeutics Inc (NASDAQ:DNLI) insider Ryan J. Watts sold 18,333 shares of Denali Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $19.07, for a total transaction of $349,610.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ DNLI traded up $0.22 during midday trading on Friday, reaching $20.76. 246,088 shares of the stock were exchanged, compared to its average volume of 385,639. The business’s 50-day moving average is $20.08. The stock has a market capitalization of $1.98 billion, a P/E ratio of -53.23 and a beta of 2.28. Denali Therapeutics Inc has a 12 month low of $12.32 and a 12 month high of $28.86. The company has a quick ratio of 11.55, a current ratio of 11.55 and a debt-to-equity ratio of 0.14.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. Equities research analysts anticipate that Denali Therapeutics Inc will post -1.48 earnings per share for the current year.

A number of equities analysts have recently weighed in on DNLI shares. ValuEngine raised shares of Denali Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, March 11th. Zacks Investment Research cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 12th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.50.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in Denali Therapeutics in the 1st quarter valued at approximately $359,000. Dynamic Technology Lab Private Ltd bought a new position in Denali Therapeutics in the 1st quarter valued at approximately $397,000. Ironwood Investment Management LLC lifted its stake in Denali Therapeutics by 124.0% in the 1st quarter. Ironwood Investment Management LLC now owns 22,607 shares of the company’s stock valued at $525,000 after purchasing an additional 12,515 shares during the last quarter. Wasatch Advisors Inc. lifted its stake in Denali Therapeutics by 1,702.4% in the 1st quarter. Wasatch Advisors Inc. now owns 820,904 shares of the company’s stock valued at $19,061,000 after purchasing an additional 775,358 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Denali Therapeutics by 29.4% in the 1st quarter. New York State Common Retirement Fund now owns 57,820 shares of the company’s stock valued at $1,343,000 after purchasing an additional 13,120 shares during the last quarter. 71.69% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: What is a capital gains distribution?

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.